Corpus ID: 27708641

The role of anti-Müllerian hormone in diagnosing and managing PCOS

  title={The role of anti-M{\"u}llerian hormone in diagnosing and managing PCOS},
  • Published 2016 Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting females of reproductive age and the leading cause of anovulatory infertility.1 Lack of correct diagnosis and management of PCOS can lead to reproductive challenges (e.g., infertility, early miscarriage, gestational diabetes), metabolic disorders (e.g., type 2 diabetes mellitus), or cardiovascular disorders (e.g., hypertension, dyslipidemia).2 Advanced practice nurses (APNs) are tasked with… Expand


The management of patients with polycystic ovary syndrome
Ovulation rate is improved by diet and lifestyle intervention in overweight individuals but induction of ovulation by, in the first instance, anti-estrogens is usually required; monitoring of glucose is important in overweight women and/or those with a family history of T2DM. Expand
The role of serum anti-Müllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome
  • L. Casadei, A. Madrigale, +4 authors D. Dewailly
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2013
The data confirms that the AMH assay has a high diagnostic potential, providing that an appropriate threshold is used, and may be included as an ultimate diagnostic criterion for the diagnosis of PCOS when either HA or anovulation is missing and/or when no reliable antral follicle count can be obtained. Expand
Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms
The serum AMH level is a useful diagnostic marker for PCOS and is correlated with conventional diagnostic criteria and can be introduced as a possible objective criterion for the diagnosis of this disease. Expand
Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies.
  • M. Lujan, D. Chizen, R. Pierson
  • Medicine
  • Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
  • 2008
Clinical signs of hyperandrogenism are ill-defined in women with PCOS, and the diagnosis of both hirsutism and polycystic ovarian morphology remains alarmingly subjective, so there is an inappropriate tendency to assign ovulatory status solely on the basis of menstrual cycle history or poorly timed endocrine measurements. Expand
Anti-Műllerian hormone – a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome
Assessment of AMH as a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome found it a useful predictive marker for the treatment efficiency. Expand
Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries.
For the definition of PCOM, the former threshold of >12 for FN is no longer valid and a serum AMH >35 pmol/l appears to be more sensitive and specific than a FN >19 and should be included in the current diagnostic classifications for PCOS. Expand
Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin.
AMH levels are significantly elevated in women with PCOS and they may serve as a marker for evaluation of treatment efficacy with metformin, and obese PCOS patients are more likely to respond to meetformin therapy with maximal doses as compared to the ones with low body mass index. Expand
Anti mullerian hormone: a potential marker for recruited non growing follicle of ovarian pool in women with polycystic ovarian syndrome.
The diagnostic potency of Area Under Curve (AUC) for AMH in infertile subjects reflects that AMH is a potential marker for recruited non growing follicles rather than a simple marker for ovarian reserve as it is predominantly produced by small follicles. Expand
Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.
The data suggest that the increase of AMH serum level in PCOS is the consequence of the androgen-induced excess in small antral FN and that each follicle produces a normal amount ofAMH. Expand
The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome.
The higher AMH/AFC in women with PCOM only than in controls suggests that isolated PCOM may represent a PCOS-like phenotype in which an inherent dysfunction of GC exists but is too mild to affect the ovulatory process. Expand